# Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/denosumab-versus-zoledronic-acid-for-treatment-of-bone-metastases-in-men-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damião,Janet E. Brown,Lawrence I. Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,Huei Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl |
| Citations | 1,972 |
| DOI | 10.1016/s0140-6736(10)62344-6 |
| Fields | Medicine |
| Open Access | true |
| OA Status | green |
| OA URL | https://www.ncbi.nlm.nih.gov/pmc/articles/3090685 |
| OpenAlex ID | https://openalex.org/W2139860898 |
| PMID | 21353695 |
| Type | article |
| Year | 2011 |

## Paper authors

- [Michael A. Carducci](https://scholariq.org/researchers/michael-a-carducci/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Bone health and treatments](https://scholariq.org/topics/bone-health-and-treatments/)

## Paper topics

- [Bone health and treatments](https://scholariq.org/topics/bone-health-and-treatments/)
- [Prostate Cancer Treatment and Research](https://scholariq.org/topics/prostate-cancer-treatment-and-research/)
- [Management of metastatic bone disease](https://scholariq.org/topics/management-of-metastatic-bone-disease/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.